Last reviewed · How we verify
subcutanious administration — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
subcutanious administration (subcutanious administration) — GlaxoSmithKline.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| subcutanious administration TARGET | subcutanious administration | GlaxoSmithKline | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- subcutanious administration CI watch — RSS
- subcutanious administration CI watch — Atom
- subcutanious administration CI watch — JSON
- subcutanious administration alone — RSS
Cite this brief
Drug Landscape (2026). subcutanious administration — Competitive Intelligence Brief. https://druglandscape.com/ci/subcutanious-administration. Accessed 2026-05-15.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab